RegulatoryJul 16, 2026, 04:31 PM
Cellyan Biotechnology Gets Nasdaq Extension to Regain $1 Bid Price
AI Summary
Cellyan Biotechnology Co., Ltd received a notification from Nasdaq's Listing Qualifications Department, granting an additional 180-day period until January 11, 2027, to regain compliance with the minimum $1.00 closing bid price requirement. To comply, the company must maintain a closing bid price of at least $1.00 for ten consecutive business days. Cellyan Biotechnology plans to implement feasible solutions, including a potential reverse share split, to restore its Nasdaq listing, though there is no assurance of success. The company's shares will continue to trade uninterrupted during this period.
Key Highlights
- Received Nasdaq notification on July 14, 2026, regarding minimum bid price non-compliance.
- Granted an additional 180-calendar day extension until January 11, 2027.
- Must maintain a closing bid price of at least $1.00 for ten consecutive business days.
- Company plans to coordinate feasible solutions to restore listing compliance.
- Potential solutions include effecting a reverse share split if necessary.
- Company's Class A ordinary shares continue to trade uninterrupted on Nasdaq under HKPD.
Price Impact